Clinical Trial 45963

Long Beach, CA 90806


The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with PD-MCI.

  • Meet the following criteria for PD-MCI: Have a confirmed diagnosis of idiopathic PD according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria; Meet MDS Task Force Criteria for MCI in PD.
  • Have a score of 20 to 25 (inclusive) on the Montreal Cognitive Assessment (MoCA) at Screening.
  • Meet criteria for Hoehn & Yahr Stage I to III (mild to moderate motor severity) at Screening.
  • Have stable motor symptoms for at least 4 weeks prior to screening, in the opinion of the investigator.

Qualified Participants May Receive:

Compensation for participating up to $900.00 over the study length (28 days)

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.